Table 3.
The collected biomarkers of all meta-analyzed studies of statistical significance with calculated mean of all recorded means in the studies of analysis to be a help key levels for prediction of progression from a mild/moderate case of COVID-19 into severe/critical case.
| Positive COVID-19 patient | |||
|---|---|---|---|
| Biomarkers of prediction progression of cases from mild/moderate to severe/critical | |||
| Non-high-risk groupa | |||
| A-Indicators of COVID-19 progression into severe/critical condition | B-Indicators of multiorgan injury | ||
| C-reactive protein | ≥58.2 mg/L (STD 47) | LDH | ≥382 U/L (STD 221) |
| Aspartate aminotransferase (AST), U/L | ≥42.4 IU/L (STD 19.5) | ||
| Neutrophil count | ≥ 6.1 × 109/L (STD 5.8). | Albumin | ≤30.4 g/L (STD 6.1) |
| T-Lymphocytes count | ≤ 0.8 × 109/L (STD 0.46). | ||
| D-Dimer | ≥12.9 μg/mL (STD 52.7) | ||
| T Cell Function: % PD-1 expression on T cells | Creatinine | ≥77.1 μmol/L (STD 31.2) | |
| % PD-1 On T-Cell | ≥47 (STD 24) | ||
| Cytokines: | |||
| IL-6 | ≥29.6 pg/mL (STD 138) | ||
| Cortisol level: | ≥794 nmol/L (STD 264) | ||
a
Patient younger than 66.9 years (STD 15.4) with no comorbidity if show any indicator in this group considered a risk for progression into severe/ critical condition which necessitates aggressive treatment even if CT findings not clear yet and the patient condition still apparently mild.